Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...
Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... time a medicine has shown a clinical benefit in basal cell carcinoma patients who have progressed or are ...
Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...
which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung ...
One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...
Hosted on MSN2mon
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...
Hosted on MSN5mon
Regeneron Gains 13.5% Year to date: How to Play the Stock?It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...
The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ... in Non-Small Cell Lung Cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback